{"organizations": [], "uuid": "0217ce5573de16e49acff539f84c27102e9e5629", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-fibrocell-announces-fda-allowance/brief-fibrocell-announces-fda-allowance-to-initiate-pediatric-enrollment-in-phase-1-2-clinical-trial-of-fcx-007-idUSASB0C2Z2", "country": "US", "domain_rank": 408, "title": "BRIEF-Fibrocell Announces FDA Allowance To Initiate Pediatric Enrollment In Phase 1/2 Clinical Trial Of Fcx-007", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-30T15:13:00.000+02:00", "replies_count": 0, "uuid": "0217ce5573de16e49acff539f84c27102e9e5629"}, "author": "", "url": "https://www.reuters.com/article/brief-fibrocell-announces-fda-allowance/brief-fibrocell-announces-fda-allowance-to-initiate-pediatric-enrollment-in-phase-1-2-clinical-trial-of-fcx-007-idUSASB0C2Z2", "ord_in_thread": 0, "title": "BRIEF-Fibrocell Announces FDA Allowance To Initiate Pediatric Enrollment In Phase 1/2 Clinical Trial Of Fcx-007", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "epidermolysis bullosa", "sentiment": "none"}, {"name": "fibrocell science inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "clinical trial of fcx-007 reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 13 PM / in 11 minutes BRIEF-Fibrocell Announces FDA Allowance To Initiate Pediatric Enrollment In Phase 1/2 Clinical Trial Of Fcx-007 Reuters Staff 1 Min Read \nJan 30 (Reuters) - Fibrocell Science Inc: \n* FIBROCELL ANNOUNCES FDA ALLOWANCE TO INITIATE PEDIATRIC ENROLLMENT IN PHASE 1/2 CLINICAL TRIAL OF FCX-007 FOR THE TREATMENT OF RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB) \n* FIBROCELL SCIENCE INC - FCX-007, COâ€˜S GENE THERAPY CANDIDATE, IS BEING DEVELOPED IN COLLABORATION WITH INTREXON CORPORATION  ", "external_links": [], "published": "2018-01-30T15:13:00.000+02:00", "crawled": "2018-01-30T15:32:14.022+02:00", "highlightTitle": ""}